MGTA - Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m. ET.

A live webcast of the fireside chat can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations . The webcast replay will be available for 90 days following the event.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com .

Follow Magenta on Twitter: @magentatx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005121/en/

Magenta Therapeutics
Jim Haney, Senior Director, Investor Relations
317-909-4199
jhaney@magentatx.com

Lyndsey Scull, Director, Corporate Communications
202-213-7086
lscull@magentatx.com

Jill Bertotti, Real Chemistry
714-225-6726
jbertotti@realchemistry.com